Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities
Cancer is a serious threat to human beings and is the second-largest cause of death all over the globe. Chemotherapy is one of the most common treatments for cancer; however, drug resistance and severe adverse effects are major problems associated with anticancer therapy. New compounds with multi-ta...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2022-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_25bce8b65f8e44bd82dd6f2c7741a1e3 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Noor ul Amin Mohsin |e author |
| 700 | 1 | 0 | |a Sana Aslam |e author |
| 700 | 1 | 0 | |a Matloob Ahmad |e author |
| 700 | 1 | 0 | |a Muhammad Irfan |e author |
| 700 | 1 | 0 | |a Sami A. Al-Hussain |e author |
| 700 | 1 | 0 | |a Magdi E. A. Zaki |e author |
| 245 | 0 | 0 | |a Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities |
| 260 | |b MDPI AG, |c 2022-11-01T00:00:00Z. | ||
| 500 | |a 10.3390/ph15121471 | ||
| 500 | |a 1424-8247 | ||
| 520 | |a Cancer is a serious threat to human beings and is the second-largest cause of death all over the globe. Chemotherapy is one of the most common treatments for cancer; however, drug resistance and severe adverse effects are major problems associated with anticancer therapy. New compounds with multi-target inhibitory properties are targeted to surmount these challenges. Cyclooxygenase-2 (COX-2) is overexpressed in cancers of the pancreas, breast, colorectal, stomach, and lung carcinoma. Therefore, COX-2 is considered a significant target for the synthesis of new anticancer agents. This review discusses the biological activity of recently prepared dual anticancer and COX-2 inhibitory agents. The most important intermolecular interactions with the COX-2 enzyme have also been presented. Analysis of these agents in the active area of the COX-2 enzyme could guide the introduction of new lead compounds with extreme selectivity and minor side effects. | ||
| 546 | |a EN | ||
| 690 | |a drug design | ||
| 690 | |a hybrid molecules | ||
| 690 | |a cancer cell lines | ||
| 690 | |a molecular docking | ||
| 690 | |a COX-2 | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceuticals, Vol 15, Iss 12, p 1471 (2022) | |
| 787 | 0 | |n https://www.mdpi.com/1424-8247/15/12/1471 | |
| 787 | 0 | |n https://doaj.org/toc/1424-8247 | |
| 856 | 4 | 1 | |u https://doaj.org/article/25bce8b65f8e44bd82dd6f2c7741a1e3 |z Connect to this object online. |